Critical limb ischemia (CLI), also known as chronic limb-threatening ischemia (CLTI), represents the most severe stage of Peripheral Artery Disease (PAD). Characterized by significantly reduced blood flow to the extremities, CLI can lead to rest pain, non-healing ulcers, and a high risk of amputation. According to Tran Minh Bao Luan et al., 2024, approximately 11% of PAD patients develop CLI. With rising prevalence due to aging populations, diabetes, and cardiovascular comorbidities, there is an urgent need for innovative therapies. The Critical Limb Ischemia Pipeline Analysis Report by Expert Market Research highlights a growing focus on regenerative medicine, gene therapy, and advanced pharmacological interventions aimed at improving limb salvage and patient quality of life.Report Coverage
This report provides comprehensive insights into over 100 pipeline drugs and more than 50 companies developing therapies for CLI. Each drug is analyzed by clinical phase, drug class, route of administration, mechanism of action, efficacy, safety outcomes, and alignment with treatment guidelines. The report evaluates ongoing product development, emerging drug delivery methods, and novel approaches designed to enhance angiogenesis, tissue repair, and symptom management in patients unsuitable for conventional interventions.
Pipeline Outlook
CLI results from advanced arterial blockages, typically due to atherosclerosis, diabetes-related vascular damage, or chronic inflammation. Standard treatments include endovascular interventions and surgical revascularization. However, patients with no-option CLI require innovative approaches. Stem cell therapies, particularly allogeneic adipose tissue-derived mesenchymal stem cell clusters (ADMSCCs), are under investigation for intramuscular administration, promoting angiogenesis, reducing ischemic pain, and improving walking distance, representing a promising alternative to conventional therapies.
Download a free sample report along with a complete table of contents for review.
Epidemiology
Globally, PAD affects over 230 million adults, with CLI constituting roughly 11% of cases. Patients with no-option CLTI experience high rates of amputation and mortality, with only 37% achieving amputation-free survival at one year (Anahita Dua et al., 2025). This emphasizes the critical need for next-generation therapeutic options.
Pipeline Assessment and Key Players
The CLI drug pipeline spans Phase I–IV trials, with Phase I and II accounting for 25% each of ongoing studies, reflecting active early- and mid-stage development. Investigational drugs include small molecules, monoclonal antibodies, peptides, gene therapies, and cell-based products. Leading players include BioGenCell Ltd., MultiGene Vascular Systems Ltd., Stempeutics Research Pvt Ltd., Boston Scientific Corporation, and others, driving forward innovative therapies to improve patient outcomes.